First patent granted to Norwood Immunology
Tuesday, 17 February, 2004
Norwood Abbey (ASX:NAL) subsidiary Norwood Immunology has been granted its first patent, covering the use of GnRH analogues to increase the T cell population for the treatment of a variety of diseases.
The patent, granted in South Africa, is the first of more than 100 patent applications filed in major jurisdictions around the world covering various aspects of the immunology project.
Director of marketing Bernie Romanin said that the granted patent provided recognition of the breadth of the application of the GnRH technology.
Norwood Immunology is in the process of listing on the London Stock Exchange's AIM market. Romanin said the listing process was progressing according to plan and the company expected it to list mid-year.
Accurate age estimation with DNA methylation
Using cutting-edge artificial intelligence, scientists created a tool that can determine a...
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...